Ablynx NV recorded significant gains in 2013 in both financial and drug development spheres. Cash income from its collaborations with larger pharmaceutical companies increased fourfold to €157.6 million from €36.5 million a year earlier while the net loss for the period narrowed to €19.5 million.
